Summit Therapeutics Inc
SMMT23.465USD
-13.235-36.06%
收盤 04/25, 16:00（美東）報價延遲15分鐘
17.31B總市值
虧損本益比TTM
關於 Summit Therapeutics Inc 公司
Summit Therapeutics Inc. 是一家專注於發現、開發和商業化患者、醫生和護理人員藥物療法的生物製藥公司。該公司的開發候選藥物是 ivonescimab，這是一種潛在的同類首創雙特異性抗體，旨在將通過阻斷 PD-1 產生的免疫療法效果與抗 VEGF 化合物的抗血管生成效果結合到單個分子中。該公司開發了用於非小細胞肺癌 (NSCLC) 的 ivonescimab，具體啓動了以下適應症的 III 期臨牀試驗，例如 ivonescimab 聯合化療用於表皮生長因子受體 (EGFR) 突變、局部晚期或轉移性非鱗狀 NSCLC 患者，這些患者在接受第三代 EGFR 酪氨酸激酶抑制劑 (HARMONi) 治療後病情出現進展，以及 ivonescimab 聯合化療用於一線轉移性鱗狀 NSCLC 患者 (HARMONi-3)。其 ivonescimab 採用 Akeso 的 Tetrabody 技術設計。
公司簡介
公司代碼SMMT
公司名稱Summit Therapeutics Inc
上市日期Oct 14, 2004
成立日期2020
CEO- -
員工數量159
證券類型Ordinary Share
年結日Oct 14
公司地址601 Brickell Key Drive
城市MIAMI
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編33131
電話13052032034
網址https://www.smmttx.com/
公司代碼SMMT
上市日期Oct 14, 2004
成立日期2020
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.68M
+0.72%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.38M
+0.24%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Manmeet S. Soni, CPA
Mr. Manmeet S. Soni, CPA
Chief Financial Officer, Chief Operating Officer, Director
Chief Financial Officer, Chief Operating Officer, Director
--
--
Dr. Robert F. Booth, Ph.D.
Dr. Robert F. Booth, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Jeff Huber
Mr. Jeff Huber
Director
Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Robert William (Bob) Duggan
Mr. Robert William (Bob) Duggan
Executive Chairman of the Board, Co-Chief Executive Officer
Executive Chairman of the Board, Co-Chief Executive Officer
555.68M
+0.72%
Dr. Mahkam (Maky) Zanganeh
Dr. Mahkam (Maky) Zanganeh
President, Co-Chief Executive Officer, Director
President, Co-Chief Executive Officer, Director
35.38M
+0.24%
Dr. Yu (Michelle) Xia
Dr. Yu (Michelle) Xia
Non-Executive Director
Non-Executive Director
31.52M
--
Mr. Robert Lacaze
Mr. Robert Lacaze
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Kenneth A. Clark, J.D.
Mr. Kenneth A. Clark, J.D.
Lead Non-Executive Independent Director
Lead Non-Executive Independent Director
--
--
Dr. Mostafa Ronaghi, Ph.D.
Dr. Mostafa Ronaghi, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明細
單位: USD更新時間: 4月6日 週日
單位: USD更新時間: 4月6日 週日
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
暫無數據
地區USD
名稱
營收
佔比
Latin America
0.00
0.00%
業務
地區
暫無數據
股東統計
更新時間: 2月21日 週五
更新時間: 2月21日 週五
持股股東
股東類型
持股股東
股東統計
佔比
Duggan (Robert William)
75.35%
Zanganeh (Mahkam)
4.80%
Xia (Yu)
4.27%
Baker Bros. Advisors LP
3.31%
The Vanguard Group, Inc.
1.58%
Other
10.68%
持股股東
股東統計
佔比
Duggan (Robert William)
75.35%
Zanganeh (Mahkam)
4.80%
Xia (Yu)
4.27%
Baker Bros. Advisors LP
3.31%
The Vanguard Group, Inc.
1.58%
Other
10.68%
股東類型
股東統計
佔比
Individual Investor
84.90%
Investment Advisor
4.57%
Hedge Fund
4.06%
Investment Advisor/Hedge Fund
3.86%
Research Firm
0.40%
Pension Fund
0.02%
Bank and Trust
0.02%
Sovereign Wealth Fund
0.01%
Other
2.16%
機構持股
更新時間: 1月20日 週一
更新時間: 1月20日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
388
717.78M
97.33%
+5.71M
2024Q4
388
717.73M
97.33%
+5.42M
2024Q3
325
708.90M
96.17%
+11.45M
2024Q2
260
692.13M
98.13%
+14.08M
2024Q1
228
669.32M
95.38%
+36.91M
2023Q4
210
620.08M
88.82%
-5.65M
2023Q3
205
616.45M
88.38%
+11.96M
2023Q2
199
619.05M
88.77%
+407.10M
2023Q1
178
604.96M
86.79%
+406.66M
2022Q4
154
191.34M
95.05%
+13.11M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Duggan (Robert William)
551.70M
74.81%
+3.33M
+0.61%
Sep 13, 2024
Zanganeh (Mahkam)
35.38M
4.8%
+84.32K
+0.24%
Apr 17, 2024
Xia (Yu)
31.52M
4.27%
--
--
Apr 17, 2024
Baker Bros. Advisors LP
24.42M
3.31%
--
--
Dec 31, 2024
The Vanguard Group, Inc.
11.67M
1.58%
+724.04K
+6.61%
Dec 31, 2024
Fidelity Management & Research Company LLC
8.02M
1.09%
-277.94K
-3.35%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
7.55M
1.02%
+402.22K
+5.63%
Dec 31, 2024
T. Rowe Price Associates, Inc.
6.47M
0.88%
+1.11M
+20.72%
Dec 31, 2024
State Street Global Advisors (US)
5.60M
0.76%
+2.13M
+61.54%
Dec 31, 2024
Geode Capital Management, L.L.C.
3.20M
0.43%
+101.04K
+3.26%
Dec 31, 2024
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
Tema Oncology ETF
2.77%
Invesco Nasdaq Biotechnology ETF
1.46%
ProShares Ultra Nasdaq Biotechnology
1.42%
Range Cancer Immunotherapy ETF
1.24%
Virtus LifeSci Biotech Clinical Trials ETF
1.04%
SPDR S&P Biotech ETF
0.92%
Invesco NASDAQ Next Gen 100 ETF
0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
0.67%
Direxion Daily S&P Biotech Bull 3X Shares
0.58%
Simplify Next Intangible Core Index ETF
0.35%
查看更多
Tema Oncology ETF
佔比2.77%
Invesco Nasdaq Biotechnology ETF
佔比1.46%
ProShares Ultra Nasdaq Biotechnology
佔比1.42%
Range Cancer Immunotherapy ETF
佔比1.24%
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.04%
SPDR S&P Biotech ETF
佔比0.92%
Invesco NASDAQ Next Gen 100 ETF
佔比0.89%
Invesco ESG NASDAQ Next Gen 100 ETF
佔比0.67%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.58%
Simplify Next Intangible Core Index ETF
佔比0.35%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據